US 11,780,970 B2
Carbohydrate crosslinker
Hotan Mojarradi, Uppsala (SE); Johan Olsson, Bromma (SE); Craig Harris, Biot (FR); Jean-Guy Boiteau, Valbonne (FR); Thibaut Gerfaud, Mouans Sartoux (FR); and Loïc Tomas, Biot (FR)
Assigned to GALDERMA HOLDING S.A., Zug (CH)
Filed by Galderma Holding SA, Zug (CH)
Filed on Mar. 15, 2023, as Appl. No. 18/184,439.
Application 18/184,439 is a continuation of application No. 18/071,282.
Application 18/071,282 is a continuation of application No. 16/066,810, granted, now 11,530,301, issued on Dec. 20, 2022, previously published as PCT/EP2016/082783, filed on Dec. 28, 2016.
Claims priority of application No. 15202944 (EP), filed on Dec. 29, 2015; application No. 16172225 (EP), filed on May 31, 2016; application No. 16172241 (EP), filed on May 31, 2016; and application No. 16172254 (EP), filed on May 31, 2016.
Prior Publication US 2023/0212360 A1, Jul. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 8/04 (2006.01); A61K 8/73 (2006.01); A61P 17/00 (2006.01); A61Q 19/00 (2006.01); A61K 9/00 (2006.01); C08B 37/08 (2006.01); C08K 5/09 (2006.01); C08K 5/08 (2006.01); C07C 209/62 (2006.01); C07C 7/08 (2006.01); C07C 213/00 (2006.01); C08J 3/24 (2006.01); C08J 3/075 (2006.01); C08L 5/00 (2006.01); C08J 7/14 (2006.01); C07C 269/06 (2006.01); C08B 37/00 (2006.01); C08L 5/08 (2006.01); C07F 7/08 (2006.01)
CPC C08J 3/075 (2013.01) [A61K 8/042 (2013.01); A61K 8/73 (2013.01); A61K 8/735 (2013.01); A61K 9/0019 (2013.01); A61Q 19/00 (2013.01); C07C 209/62 (2013.01); C07C 213/00 (2013.01); C07C 269/06 (2013.01); C07F 7/083 (2013.01); C08B 37/0063 (2013.01); C08B 37/0069 (2013.01); C08B 37/0072 (2013.01); C08J 3/24 (2013.01); C08J 7/14 (2013.01); C08K 5/09 (2013.01); C08L 5/00 (2013.01); C08L 5/08 (2013.01); C07C 2603/18 (2017.05); C08J 2305/00 (2013.01); C08J 2305/08 (2013.01)] 20 Claims
 
1. A process of preparing a hydrogel product comprising crosslinked hyaluronic acid (HA) molecules, the process comprising:
hydrolyzing via alkaline hydrolysis ester bonds in HA molecules crosslinked by diaminotrehalose (DATH) via activated carboxyl groups, to obtain a hydrogel product having less than 50% non-crosslinked HA molecules by weight of the hydrogel product.